Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc. (THRD): 8 pipeline candidates · ~61 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
60.8 months
D/E 0.03 · 0% dilution
Lead: Phase 1
8 candidates
N/A
N/A
A transparent, data-derived signal for Third Harmonic Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$271.6M
Quarterly Burn
$13.5M
Runway
60.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| inplex cf molecular test | — |
| invader ugt1a1 molecular assay | — |
| step-1 pumetch | — |
| thb001 | Phase 1 |
| thb335 | Phase 1 |
| thb335 fasted/fed | Phase 1 |
| thb335 multiple dose | Phase 1 |
| thb335 single dose | Phase 1 |
Frequently asked questions
How many drug candidates are in Third Harmonic Bio, Inc.'s pipeline?
Third Harmonic Bio, Inc. (THRD) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Third Harmonic Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Third Harmonic Bio, Inc. has approximately 60.8 months of cash runway.
Who is the CEO of Third Harmonic Bio, Inc.?
Natalie Holles is the chief executive officer of Third Harmonic Bio, Inc. (THRD).
Get the full picture on Third Harmonic Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.